A disproportionality analysis of real-world events from the FDA Adverse Event Reporting System (FAERS) for Atezolizumab
Apart from various degrees of hepatotoxicity, such as increased ALT and AST, the immune-related hematological toxicity of atezolizumab should also be noted. In clinical practice, healthcare providers should always be vigilant for the occurrence of such medication-related AEs and take measures to enhance the safety of clinical medication use.
Authors
- Zhuoyang Li (ORCID: https://orcid.org/0009-0003-1631-3634)
- Xiaofeng Ou (ORCID: https://orcid.org/0000-0002-0082-6895)
- Tianhong Wang (ORCID: https://orcid.org/0000-0002-0331-3761)
- Congcong Zou
- Yuwei Liu (ORCID: https://orcid.org/0009-0005-7178-3895)
- Yan Yu (ORCID: https://orcid.org/0009-0004-0898-7951)
- Ning Zhu (ORCID: https://orcid.org/0000-0001-5902-0602)
- S. Wang
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Wuhan University of Science and Technology (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s40360-025-00879-2
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.59